Parotid-sparing radiotherapy: does it really reduce xerostomia?

Ng, M. K., Porceddu, S. V., Milnert, A. D., Corry, J., Hornby, C., Hope, G., Rischin, D. and Peters, L. J. (2005) Parotid-sparing radiotherapy: does it really reduce xerostomia?. Clinical Oncology, 17 8: 610-617. doi:10.1016/j.clon.2005.06.012


Author Ng, M. K.
Porceddu, S. V.
Milnert, A. D.
Corry, J.
Hornby, C.
Hope, G.
Rischin, D.
Peters, L. J.
Title Parotid-sparing radiotherapy: does it really reduce xerostomia?
Journal name Clinical Oncology   Check publisher's open access policy
ISSN 0936-6555
1433-2981
Publication date 2005-12-01
Year available 2005
Sub-type Article (original research)
DOI 10.1016/j.clon.2005.06.012
Open Access Status Not Open Access
Volume 17
Issue 8
Start page 610
End page 617
Total pages 8
Place of publication Camden, London, United Kingdom
Publisher W.B. Saunders
Language eng
Formatted abstract
Aim: Parotid-sparing radiotherapy (PSRT) was introduced for patients with selected head and neck cancer requiring bilateral upper-neck irradiation at our centre in 2000. The aim of this study was to compare the subjective degree of xerostomia in patients treated with PSRT between January 2000 and June 2003 with patients treated using conventional techniques (radiotherapy) over the same period.

Materials and methods: Eligible patients were required to have completed treatment 6 months previously and be recurrence-free at the time of interview. PSRT was defined as conformal radiotherapy, in which the mean dose to at least one parotid gland was 33 Gy or less, as determined by the dose-volume histogram. Patients receiving radiotherapy were treated with standard parallel-opposed fields, such that both parotids received a minimum of 40 Gy. Xerostomia was assessed using a validated questionnaire containing six questions with a rating between 0 and 10. Lower scores indicated less difficulty with xerostomia.

Results: Thirty-eight eligible patients treated with PSRT were identified: 25 with oropharyngeal cancer and 13 with nasopharyngeal cancer (NPC). The mean overall questionnaire score (Q1-5) for this group was 4.20 (standard error = 0.33). Forty-four patients (24 oropharyngeal, 21 NPC) treated with radiotherapy over the same period were eligible. The mean overall questionnaire score (Q1-5) for this group was 5.86 (standard error = 0.35). The difference in mean overall scores between the two groups of patients was statistically significant (P <0.001), as were the scores for four of the six individual questions.

Conclusion: These results suggest that PSRT offers improved long-term xerostomia-related quality of life compared with conventional radiotherapy.
Keyword Head and neck cancer
Parotid
Quality of life
Radiotherapy
Three-dimensional treatment planning
Xerostomia
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 18 Apr 2012, 22:06:49 EST by System User on behalf of Medicine - Princess Alexandra Hospital